当前位置：
X-MOL 学术
›
Eur. J. Clin. Investig.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and extreme body weight
European Journal of Clinical Investigation ( IF 4.4 ) Pub Date : 2021-07-26 , DOI: 10.1111/eci.13658 Francesca Bodega 1 , Anita Russi 1 , Francesco Melillo 1 , Fabiana Blunda 1 , Claudia Rubino 1 , Giulio Leo 1 , Alberto Cappelletti 1 , Patrizio Mazzone 2 , Paolo Mattiello 3 , Paolo Della Bella 2 , Alessandro Castiglioni 4 , Ottavio Alfieri 4 , Michele De Bonis 4 , Matteo Montorfano 5 , Moreno Tresoldi 6 , Massimo Filippi 7 , Anna Salerno 1 , Michela Cera 1 , Alberto Zangrillo 8 , Margonato Alberto 1 , Cosmo Godino 1 ,
European Journal of Clinical Investigation ( IF 4.4 ) Pub Date : 2021-07-26 , DOI: 10.1111/eci.13658 Francesca Bodega 1 , Anita Russi 1 , Francesco Melillo 1 , Fabiana Blunda 1 , Claudia Rubino 1 , Giulio Leo 1 , Alberto Cappelletti 1 , Patrizio Mazzone 2 , Paolo Mattiello 3 , Paolo Della Bella 2 , Alessandro Castiglioni 4 , Ottavio Alfieri 4 , Michele De Bonis 4 , Matteo Montorfano 5 , Moreno Tresoldi 6 , Massimo Filippi 7 , Anna Salerno 1 , Michela Cera 1 , Alberto Zangrillo 8 , Margonato Alberto 1 , Cosmo Godino 1 ,
Affiliation
Limited clinical data exist describing the use of direct oral anticoagulants (DOACs) in patient with extreme body weight. Thus, the International Society of Thrombosis and Haemostasis (ISTH) recommends avoiding DOACs in patients with weight >120 Kg, and on the contrary, no restrictions exist for underweight patients.
中文翻译：
非瓣膜性心房颤动和极端体重患者的直接口服抗凝剂
有限的临床数据描述了在极端体重患者中使用直接口服抗凝剂 (DOAC)。因此，国际血栓和止血协会 (ISTH) 建议体重 >120 Kg 的患者避免使用 DOAC，相反，体重过轻的患者没有限制。
更新日期：2021-07-26
中文翻译：
非瓣膜性心房颤动和极端体重患者的直接口服抗凝剂
有限的临床数据描述了在极端体重患者中使用直接口服抗凝剂 (DOAC)。因此，国际血栓和止血协会 (ISTH) 建议体重 >120 Kg 的患者避免使用 DOAC，相反，体重过轻的患者没有限制。
京公网安备 11010802027423号